MGC Pharmaceuticals Limited
MGCLF · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Revenue | $3 | $5 | $3 | $2 |
| % Growth | -28.4% | 57.9% | 44.1% | – |
| Cost of Goods Sold | $3 | $3 | $2 | $2 |
| Gross Profit | $1 | $2 | $1 | -$0 |
| % Margin | 38% | 33% | 24.6% | -14.7% |
| R&D Expenses | $2 | $3 | $6 | $5 |
| G&A Expenses | $14 | $9 | $7 | $4 |
| SG&A Expenses | $15 | $10 | $8 | $4 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | -$0 | -$0 | $1 | -$2 |
| Operating Expenses | $17 | $14 | $13 | $12 |
| Operating Income | -$15 | -$15 | -$12 | -$12 |
| % Margin | -457.3% | -327.5% | -398.5% | -567.8% |
| Other Income/Exp. Net | -$6 | -$5 | -$4 | -$7 |
| Pre-Tax Income | -$21 | -$21 | -$16 | -$19 |
| Tax Expense | $0 | -$0 | -$1 | -$0 |
| Net Income | -$21 | -$20 | -$16 | -$19 |
| % Margin | -614.6% | -430% | -529.7% | -931.4% |
| EPS | -7.1 | -7.9 | -8.3 | -14 |
| % Growth | 10.1% | 4.8% | 40.7% | – |
| EPS Diluted | -7.07 | -7.9 | -8.3 | -14 |
| Weighted Avg Shares Out | 3 | 3 | 2 | 1 |
| Weighted Avg Shares Out Dil | 3 | 3 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $1 | $0 |
| EBITDA | -$20 | -$15 | -$17 | -$19 |
| % Margin | -601.6% | -320.4% | -569.1% | -897.6% |